373
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

The Prevalence of Coagulopathy and Associated Factors Among Adult Type II Diabetes Mellitus Patients Attending the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia

ORCID Icon, ORCID Icon, & ORCID Icon
Pages 579-590 | Published online: 24 Feb 2022

References

  • American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37:S81–S90. doi:10.2337/dc14-S081
  • Thomas C, Philipson LH. Update on diabetes classification. Med Clin. 2015;99(1):1–16. doi:10.1016/j.mcna.2014.08.015
  • American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2014;37(Supplement 1):S14–S80. doi:10.2337/dc14-S014
  • Alam U, Asghar O, Azmi S, Malik RA. General aspects of diabetes mellitus. Handb Clin Neurol. 2014;126:211–222.
  • Roglic G, Varghese C, Cowan M. Global Report on Diabetes (World Health Organization). WHO Library Cataloguing-In-Publication Data. WHO; 2016.
  • Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia. 1993;36(11):1119–1125. doi:10.1007/BF00401055
  • Kottke-Marchant K, Corcoran G. The laboratory diagnosis of platelet disorders. Archiv Pathol Lab Med. 2002;126(2):133–146. doi:10.5858/2002-126-0133-TLDOPD
  • Morel O, Jesel L, Abbas M, Morel N. Prothrombotic changes in diabetes mellitus. Semin Thromb Hemost. 2013;39(5):477–488. doi:10.1055/s-0033-1343888
  • Kershaw G, Orellana D. Mixing tests: diagnostic aides in the investigation of prolonged prothrombin times and activated partial thromboplastin times. Semin Thromb Hemost. 2013;39(3):283–290. doi:10.1055/s-0033-1336832
  • Kershaw G, Jayakodi D, Dunkley S. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center. Semin Thromb Hemost. 2009;35(8):760–768. doi:10.1055/s-0029-1245108
  • Kershaw G, Favaloro EJ. Laboratory identification of factor inhibitors: an update. Pathology. 2012;44(4):293–302. doi:10.1097/PAT.0b013e328353254d
  • Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications. 2001;15(1):44–54. doi:10.1016/S1056-8727(00)00132-X
  • Chan P, Pan WH. Coagulation activation in type 2 diabetes mellitus: the higher coronary risk of female diabetic patients. Diabet Med. 1995;12(6):504–507. doi:10.1111/j.1464-5491.1995.tb00532.x
  • Mwambungu A, Kaile T, Korolova L, Kwenda J, Marimo C. Risk factors associated with hypercoagulability in type 2 diabetes mellitus patients at Ndola Central Hospital Zambia. Med J Zambia. 2014;41(2):70–80.
  • Sosothikul D, Seksarn P, Lusher JM. Pediatric reference values for molecular markers in hemostasis. J Pediatr Hematol Oncol. 2007;29(1):19–22. doi:10.1097/MPH.0b013e3180308749
  • Shetty S, Ghosh K, Mohanty D. Comparison of four commercially available activated partial thromboplastin time reagents using a semi-automated coagulometer. Blood Coagulat Fibrinoly. 2003;14(5):493–497. doi:10.1097/00001721-200307000-00011
  • Benzon HT, Park M, McCarthy RJ, Kendall MC, Lindholm PF. Mixing studies in patients with prolonged activated partial thromboplastin time or prothrombin time. Anesthes Analges. 2019;128(6):1089–1096. doi:10.1213/ANE.0000000000003457
  • Horlocker TT, Vandermeulen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society Of Regional Anesthesia And Pain Medicine evidence-based guidelines. Region Anesthes Pain Med. 2018;43(3):263–309. doi:10.1097/AAP.0000000000000763
  • Smit C, Hallett TB, Lange J, Garnett G, de Wolf F. Late entry to HIV care limits the impact of anti-retroviral therapy in The Netherlands. PLoS One. 2008;3(4):e1949. doi:10.1371/journal.pone.0001949
  • International Diabetes Federation. IDF diabetes atlas, 9th edn. Brussels, Belgium; 2019:36–64. Available from: https://www.diabetesatlas.org. Accessed February 15, 2022.
  • Colagiuri S, Guariguata L, Motala A, Ogurtsova K. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9 (th) edition. Diabetes Res Clin Pract. 2019;157:107843. doi:10.1016/j.diabres.2019.107843
  • International Diabetes Federation. IDF Africa members, Ethiopia; 2020. Available from: https://idf.org/our-network/regions-members/africa/members/9-ethiopia.html. Accessed February 15, 2022.
  • Asrat D, Tesfaye G, Gedefaw L, Addisu W, Yemane T. Hemostatic abnormality and associated factors in diabetic patients at Jimma University Specialized Hospital, Jimma, Southwest Ethiopia: a comparative cross-sectional study. Ethiop J Health Sci. 2019;29(2):253–256.
  • Ambelu YA, Shiferaw MB, Abebe M, Enawgaw B. Prothrombin time, activated partial thromboplastin time and platelet counts of type II diabetes mellitus: a comparative study. J Diabetes Metabol Disord. 2018;17(2):117–121. doi:10.1007/s40200-018-0347-5
  • Population Census Commission. Summary and statistical report of the 2007 population and housing census. Population size by age and sex. 2008:314.
  • Deressa T, Damtie D, Workineh M, Genetu M, Melku MJE. Anemia and thrombocytopenia in the cohort of HIV-infected adults in northwest Ethiopia: a facility-based cross-sectional study. EJIFCC. 2018;29(1):36.
  • Aynalem M, Shiferaw E, Gelaw Y, Enawgaw B. Coagulopathy and its associated factors among patients with a bleeding diathesis at the University of Gondar Specialized Referral Hospital, Northwest Ethiopia. Thromb J. 2021;19(1):36. doi:10.1186/s12959-021-00287-6
  • Keohane EM, Otto CN, Walenga JM. Rodak’s Hematology-E-Book: Clinical Principles and Applications. Elsevier Health Sciences; 2019.
  • Patel SM, Gupta S, Patel MM, Mahadik JD, Patel KA, Patel AS. A study of coagulation profile in neoplastic conditions. Int J Med Sci Public Health. 2016;5(3):402–408. doi:10.5455/ijmsph.2016.1807201565
  • World Health Organization. The Global Prevalence of Anemia in 2011. Geneva: WHO; 2015.
  • Sultan A. Five-minute preparation of platelet-poor plasma for routine coagulation testing. East Mediterr Health J. 2010;16(2):233–236. doi:10.26719/2010.16.2.233
  • Ignjatovic V. Prothrombin time/international normalized ratio. Methods Mol Biol. 2013;992:121–129.
  • Ignjatovic V. Activated partial thromboplastin time. Methods Mol Biol. 2013;992:111–120.
  • Miller CH. Chapter 130 - mixing studies. In: Shaz BH, Hillyer CD, Reyes Gil M, editors. Transfusion Medicine and Hemostasis. Third ed. Elsevier; 2019:783–784.
  • Chotivanich K, Silamut K, Day N. Laboratory diagnosis of malaria infection. Austr J Med Sci. 2006;27(1):11.
  • Owaidah T, Saleh M, Alzahrani H, et al. Prevalence of bleeding symptoms among adolescents and young adults in the capital city of Saudi Arabia. Adv Hematol. 2018;2018:1858241. doi:10.1155/2018/1858241
  • Ephraim RK, Awuku YA, Adu P, et al. High risk of coagulopathy among type-2 diabetes mellitus clients at a municipal hospital in Ghana. Ghana Med J. 2017;51(3):101–107. doi:10.4314/gmj.v51i3.2
  • Ilyas S, Waheed U, Saboor M. Coagulation abnormalities in diabetes mellitus. J Public Health Biol Sci. 2013;2(4):308–312.
  • Yürekli BP, Ozcebe OI, Kirazli S, Gürlek A. Global assessment of the coagulation status in type 2 diabetes mellitus using rotation thromboelastography. Blood Coagul Fibrinolysis. 2006;17(7):545–549. doi:10.1097/01.mbc.0000245292.34150.df
  • Asrat D, Tesfaye G, Gedefaw L, Addisu W, Yemane T. Hemostatic abnormality and associated factors in diabetic patients at Jimma University Specialized Hospital, Jimma, Southwest Ethiopia: a Comparative Cross-sectional Study. Ethiop J Health Sci. 2019;29(2):251–258. doi:10.4314/ejhs.v29i2.12
  • Al-Rubeaan K, Nawaz SS, Youssef AM, Al Ghonaim M, Siddiqui K. IL-18, VCAM-1 and P-selectin as early biomarkers in normoalbuminuric type 2 diabetes patients. Biomark Med. 2019;13(6):467–478. doi:10.2217/bmm-2018-0359
  • Madan R, Gupt B, Saluja S, Kansra U, Tripathi B, Guliani BJ. Coagulation profile in diabetes and its association with diabetic microvascular complications. The Journal of the Association of Physicians of India. 2010;58:481–484.
  • Grant P. Diabetes mellitus as a prothrombotic condition. J Intern Med. 2007;262(2):157–172. doi:10.1111/j.1365-2796.2007.01824.x
  • Ebrahim H, Asrie F, Getaneh Z. Basic coagulation profiles and platelet parameters among adult type 1 and type 2 diabetes patients at Dessie Referral Hospital, Northeast Ethiopia: comparative cross-sectional study. J Blood Med. 2021;12:33–42. doi:10.2147/JBM.S287136
  • Ankalayya B, Sodhi H, Modala S, Baghel M. A comparative study of coagulation time in type 2 diabetes mellitus and healthy individuals. Int J Contemp Med Res. 2016;3(11):3170–3171.
  • Mariappan A, Deepa V, Nagendran R. Evaluation of coagulation profile in patients suffering with type-2 diabetes mellitus: a hospital based prospective study. Int J Clin Biochem Res. 2020;5(1):97–100.
  • Karim F, Akter QS, Jahan S, et al. Coagulation impairment in type 2 diabetes mellitus. J Bangla Soc Physiol. 2015;10(1):26–29. doi:10.3329/jbsp.v10i1.24614
  • Pan L, Ye Y, Wo M, et al. Clinical significance of hemostatic parameters in the prediction for type 2 diabetes mellitus and diabetic nephropathy. Dis Markers. 2018;2018:2–3. doi:10.1155/2018/5214376
  • Sapkota B, Shrestha SK, Poudel S. Association of activated partial thromboplastin time and fibrinogen level in patients with type II diabetes mellitus. BMC Res Notes. 2013;6(1):485. doi:10.1186/1756-0500-6-485
  • Alao O, Damulak D, Joseph D, Puepet F. Haemostatic profile of patients with type 2 diabetes mellitus in Northern Nigeria. Internet J Endocrinol. 2009;6(1):1–4.
  • Mohammed O. Alteration in prothrombin time, INR, partial thromboplastin time and platelets in type 2 diabetes mellitus, cross-sectional study-Sudan. World J Adv Res Rev Cardiovasc Med. 2020;5(3):129–133. doi:10.30574/wjarr.2020.5.3.0065
  • Thukral S, Hussain S, Bhat S, Kaur N, Reddy A. Prothrombin time (PT) and activated partial thromboplastin time (APTT) in type 2 diabetes mellitus, a case control study. Int J Contemp Med Res. 2018;5(8):H5–H9.
  • Ifeanyi OE, Chukwuemeka OH, Sunday AG, Uche EC. Changes in some coagulation parameters among diabetic patients in Michael Okpara university of agriculture, Umudike, Abia state, Nigeria. World J Pharma Pharma Sci. 2014;3(4):52–61.
  • Shimizu H. Thrombocytopenia in insulin-dependent diabetes mellitus. Kitakanto Med J. 1998;48(4):283–285. doi:10.2974/kmj.48.283
  • Madan R, Gupt B, Saluja S, Kansra U, Tripathi B, Guliani B. Coagulation profile in diabetes and its association with diabetic microvascular complications. Assoc Physicians India. 2010;58:481–484.
  • Soliman GZ. Abnormalities in plasma concentration of lipids and fibrinogen of Egyptian microalbuminuric NIDDM type 2 diabetic patients. Egypt J Hosp Med. 2005;21(1):66–81. doi:10.21608/ejhm.2005.18050
  • Mansfield MW, Heywood DM, Grant PJ. Sex differences in coagulation and fibrinolysis in white subjects with non–insulin-dependent diabetes mellitus. Arterioscleros Thrombos Vasc Biol. 2002;16(1):160–164. doi:10.1161/01.ATV.16.1.160
  • Reaven GM, Scott EM, Grant PJ, et al. Hemostatic abnormalities associated with obesity and the metabolic syndrome. J Thrombos Haemost. 2005;3(5):1074–1085. doi:10.1111/j.1538-7836.2005.01277.x
  • Samad F, Ruf W. Inflammation, obesity, and thrombosis. Blood. 2013;122(20):3415–3422. doi:10.1182/blood-2013-05-427708